Tags

Type your tag names separated by a space and hit enter

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Parkinsonism Relat Disord. 2005 Jun; 11(4):253-6.PR

Abstract

Hyperhomocysteinemia is not only a major risk factor for atherothrombotic disease, but is also strongly associated with an increased risk of dementia and cognitive impairment, both of which are common in the course of Parkinson's disease (PD). Previous work has found that levodopa increases plasma homocysteine concentrations. Animal studies have indicated that the catechol-O-methyltransferase (COMT) inhibitors can prevent levodopa-induced elevation of homocysteine concentrations by reducing the O-methylation of levodopa. The objective of our study was to assess the impact of entacapone, a COMT inhibitor, on plasma levels of homocysteine, serum folate, and vitamin B12 in levodopa-treated PD patients. Nineteen PD patients receiving only levodopa and 21 PD patients on a combination of levodopa and entacapone participated in the cross-sectional study. The control group consisted of 17 subjects on dopamine agonists. The mean plasma homocysteine concentration in the subjects on only levodopa was higher than that in the subjects on a combination of levodopa and entacapone (P=0.001) or in the control group (P=0.0001). Concentrations of serum vitamin B12 and serum folate were on average normal in all groups, but levodopa-treated subjects (with or without entacapone therapy) were more prone to have hypovitaminosis B12 (45%) than controls on dopamine agonists (6%). We suggest that the COMT inhibition may play a promising role in successfully controlling levodopa-induced hyperhomocysteinemia and in reducing the risk of pathologies probably linked to it. These preliminary findings and postulated hypotheses must now be confirmed in prospective studies.

Authors+Show Affiliations

Department of Neurology, Derer's University Hospital, Limbová 5, Bratislava 83305, Slovak Republic. valkovicpeter@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15878587

Citation

Valkovic, Peter, et al. "Reduced Plasma Homocysteine Levels in Levodopa/entacapone Treated Parkinson Patients." Parkinsonism & Related Disorders, vol. 11, no. 4, 2005, pp. 253-6.
Valkovic P, Benetin J, Blazícek P, et al. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord. 2005;11(4):253-6.
Valkovic, P., Benetin, J., Blazícek, P., Valkovicová, L., Gmitterová, K., & Kukumberg, P. (2005). Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism & Related Disorders, 11(4), 253-6.
Valkovic P, et al. Reduced Plasma Homocysteine Levels in Levodopa/entacapone Treated Parkinson Patients. Parkinsonism Relat Disord. 2005;11(4):253-6. PubMed PMID: 15878587.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. AU - Valkovic,Peter, AU - Benetin,Ján, AU - Blazícek,Pavol, AU - Valkovicová,L'udmila, AU - Gmitterová,Karin, AU - Kukumberg,Peter, Y1 - 2005/04/20/ PY - 2004/08/13/received PY - 2005/01/21/revised PY - 2005/01/21/accepted PY - 2005/5/10/pubmed PY - 2005/7/26/medline PY - 2005/5/10/entrez SP - 253 EP - 6 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 11 IS - 4 N2 - Hyperhomocysteinemia is not only a major risk factor for atherothrombotic disease, but is also strongly associated with an increased risk of dementia and cognitive impairment, both of which are common in the course of Parkinson's disease (PD). Previous work has found that levodopa increases plasma homocysteine concentrations. Animal studies have indicated that the catechol-O-methyltransferase (COMT) inhibitors can prevent levodopa-induced elevation of homocysteine concentrations by reducing the O-methylation of levodopa. The objective of our study was to assess the impact of entacapone, a COMT inhibitor, on plasma levels of homocysteine, serum folate, and vitamin B12 in levodopa-treated PD patients. Nineteen PD patients receiving only levodopa and 21 PD patients on a combination of levodopa and entacapone participated in the cross-sectional study. The control group consisted of 17 subjects on dopamine agonists. The mean plasma homocysteine concentration in the subjects on only levodopa was higher than that in the subjects on a combination of levodopa and entacapone (P=0.001) or in the control group (P=0.0001). Concentrations of serum vitamin B12 and serum folate were on average normal in all groups, but levodopa-treated subjects (with or without entacapone therapy) were more prone to have hypovitaminosis B12 (45%) than controls on dopamine agonists (6%). We suggest that the COMT inhibition may play a promising role in successfully controlling levodopa-induced hyperhomocysteinemia and in reducing the risk of pathologies probably linked to it. These preliminary findings and postulated hypotheses must now be confirmed in prospective studies. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/15878587/Reduced_plasma_homocysteine_levels_in_levodopa/entacapone_treated_Parkinson_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(05)00024-6 DB - PRIME DP - Unbound Medicine ER -